Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 174 of 6351
-
Immunotherapy combo shows promise in tough childhood cancer
Disease control CompletedThis partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotr…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Can head radiation stop lung cancer from spreading to the brain?
Prevention CancelledRATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of radiation therapy may be more effective in preventing brain metastases. PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy in prevent…
Phase 3 • Sponsor: Virginia Commonwealth University • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
Massive norwegian study aims to slash colon cancer deaths with simple screening
Prevention OngoingThe purpose of this study is to see if screening with flexible sigmoidoscopy (a flexible viewing tube) may reduce large bowel cancer and cancer deaths. The researchers also want to see if the addition of screening for occult blood in stools may contribute further to this aim. Add…
Sponsor: Norwegian Institute of Public Health • Aim: Prevention
Last updated Jun 27, 2026 12:08 UTC
-
Experimental drug offers hope for babies with rare genetic brain condition
Disease control Expanded accessMonocarboxylate Transporter 8 (MCT8) deficiency (that is also known as Allan-Herndon-Dudley syndrome) is a rare X-linked inherited disorder of brain development that causes severe intellectual disability and problems with movement. This condition, which occurs almost exclusively …
Sponsor: Roy E. Weiss, M.D. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a One-Time surgical product help regrow severed nerves?
Disease control Expanded accessThe proposed use of NTX-001 for transections of upper extremity and facial peripheral nerves, acutely or planned.
Sponsor: Neuraptive Therapeutics Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Gene therapy offers hope for sickle cell patients by boosting healthy hemoglobin
Disease control Expanded access (paused)A promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine in which genetic material (mostly DNA) in the patient is changed to treat his or her own disease. In gene therapy, we introduce new genetic materi…
Sponsor: David Williams • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Breakthrough Stent-Graft approved for deadly aortic aneurysms
Disease control ApprovedExpanded access tothe GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis is safe and effective in the treatment of thoracoabdominal and pararenal aneurysms.
Sponsor: W.L.Gore & Associates • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Lifesaving drug now available for kids with rare gut disease
Disease control ApprovedThe program is to provide access to an experimental drug called pozelimab and to document the long-term safety of pozelimab in patients with Protein-Losing Enteropathy (PLE). CD55-deficient PLE/CHAPLE disease is a rare inherited disease of the immune system. This can be a life-th…
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for kids with rare copper deficiency disease
Disease control ApprovedThis expanded access protocol provides subcutaneous copper histidinate for Menkes disease patients under 6 years of age.
Sponsor: Sentynl Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can a new eye injection beat the standard for wet AMD?
Disease control Not yet recruitingThis study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD)
Phase 2 • Sponsor: Everest Medicines (China) Co.,Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New heart pump could offer lifeline for advanced heart failure patients
Disease control Not yet recruitingTo evaluate the safety and effectiveness of the Corheart 6 left ventricular assist system in providing mechanical support for blood circulation in patients with advanced left ventricular heart failure.
Sponsor: Shenzhen Core Medical Technology CO.,LTD. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a monthly shot keep Kids' inherited high cholesterol in check for years?
Disease control Not yet recruitingThe goal is to assess the long term efficacy (LDL cholesterol reduction) and safety over 3 years of lerodalcibep (Lerochol) SC 300 mg QM administered by auto-injector (AI)/pre-filled pen (PFP) in male and female pediatric patients 6 to 17 years of age, with inherited high cholest…
Phase 3 • Sponsor: LIB Therapeutics LLC • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can Gene-Edited immune cells tame Hard-to-Treat cancers?
Disease control Not yet recruitingThe goal of this Phase 1/2a interventional study is to evaluate the safety and tolerability of CRG-150 in relapsed/refractory HR+HER2- breast cancer, Triple Negative Breast Cancer (TNBC) and prostate cancer. The main questions it aims to answer are: Phase 1 * Incidence of DLTs …
Phase 1/2 • Sponsor: CoRegen, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Beyond the genome: new Multi-Omics approach aims to crack the code of intellectual disability
Diagnosis Not yet recruitingNeurodevelopmental disorders (NDDs), including intellectual disability (ID), represent the most common indication for genetic testing. Affecting up to 3% of the general population, NDDs are characterized by significant clinical and genetic heterogeneity. Although short-read genom…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Could a simple dural patch boost recovery after spinal cord injury?
Disease control Not yet recruitingThe goal of this clinical trial is to learn whether expansile duraplasty can improve neurological recovery in adult patients with acute severe traumatic spinal cord injury, as well as evaluate the safety of this surgical strategy. The main questions the study aims to answer are: …
Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Triple-Drug combo outsmart advanced pancreatic cancer?
Disease control Not yet recruitingThis is a prospective, open-label, single-arm clinical study designed to evaluate the efficacy and safety of retlirafusp alfa combined with apatinib and chemotherapy as second-line treatment in patients with unresectable locally advanced or metastatic pancreatic cancer who have e…
Phase 2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a Triple-Drug combo outsmart a rare and aggressive cancer?
Disease control Not yet recruitingThe aim of this prospective, randomized, controlled clinical trial is to evaluate the efficacy and safety of iparomlimab and tuvonralimab injection (QL1706) plus lenvatinib and etoposide-based platinum chemotherapy, consisting of etoposide plus cisplatin or carboplatin, compared …
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Drug combo aims to shrink NF2 tumors and save hearing
Disease control Not yet recruitingThis is an investigator-initiated, exploratory, multicenter, open-label, single-arm clinical trial and a substudy of the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2). The study aims to evaluate the safety, tolerability, and preliminary efficacy of luvometinib…
Phase 1/2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Weekly shot could help shed pounds in obesity trial
Disease control Not yet recruitingThis randomized, double-blind, parallel, placebo-controlled phase Ⅲ study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients
Phase 3 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can targeted electrical pulses quiet an erratic heartbeat?
Disease control Not yet recruitingThis clinical investigation is intended to demonstrate safety and effectiveness of the PulseMagic™ TrueForce™ Ablation Catheter and the PulseMagic™Pulse Field Ablation (PFA) Generator, and Columbus™ 3D EP Navigation System with Pulsed Field Ablation Software for the treatment of …
Sponsor: Shanghai MicroPort EP MedTech Co., Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC